TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17927576
Drug: Retinoic acid
Normalized name: Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Retinoic acid therapy
Study: 15784032
Drug: Indomethacin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (25 mg, three times daily for 6 months)
Study: 1754846
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate (CBS), two tablets twice daily for 4 weeks
Study: 7022484
Drug: Sodium meclofenamate
Normalized name: Meclofenamate Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium meclofenamate (300 mg per day)
Study: 7022484
Drug: Aspirin (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (3.6 g per day)
Study: 28951663
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg i.v. ibuprofen
Study: 28951663
Drug: saline without
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline without ibuprofen
Study: 27290966
Drug: High-dose remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose remifentanil infusion
Study: 27290966
Drug: Low-dose remifentanil
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose remifentanil infusion
Study: 19045974
Drug: Community Treatment
Normalized name: ALCOHOL 80 mL in 100 mL TOPICAL LIQUID [Sanitizing Liquid for Community Support]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community Treatment by Experts (CTBE)
Study: 22954842
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality Exposure Therapy (VRE) administered for 10 treatment sessions over 5 weeks
Study: 30005843
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality Exposure Therapy (VRE)
Study: 9801179
Drug: Ondansetron hydrochloride,
Normalized name: Ondansetron Hydrochloride, 4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron hydrochloride, 4 mg intravenously
Study: 31987233
Drug: Sucrose (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (0.5 ml of oral 24% sucrose)
Study: 31987233
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sucrose and music
Study: 26691576
Drug: Adjunctive sarcosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive sarcosine (2 g/day) plus benzoate (1 g/day)
Study: 26691576
Drug: Sarcosine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarcosine (2 g/day)
Study: 25291409
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone 0.25 mg/kg/d for 7 days
Study: 21541462
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) vaccine administration
Study: 11419884
Drug: Aspirin 81
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 81 mg every third day
Study: 3539708
Drug: Ranitidine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine therapy (150 mg bd)
Study: 30463324
Drug: 500 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/d Sensoril® (S500)
Study: 24246116
Drug: Lurasidone monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone monotherapy (20-60mg/d)
Study: 24246116
Drug: Lurasidone monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone monotherapy (80-120mg/d)
Study: 24246116
Drug: Lurasidone adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone adjunctive therapy (20-120mg/d)
Study: 20569447
Drug: Methylphenidate (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (0.5 mg/kg/day)
Study: 6734037
Drug: Acetaminophen (650
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (650 mg)
Study: 17709207
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acetaminophen (325 mg) and tramadol (37.5 mg)
Study: 9438767
Drug: Pentoxifylline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (1 mg/kg of body weight per hour; maximum, 1800 mg/d)
Study: 8586774
Drug: Psyllium-enriched Step
Normalized name: STEP 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium-enriched Step I diet (3.2 g of soluble fiber per 1-oz box of cereal, 2 boxes per day)
Study: 8586774
Drug: Step I
Normalized name: Bexxar Dosimetric Step Iodine I-131 Tositumomab Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step I control diet (less than 0.5 g of soluble fiber per 1-oz box of cereal, 2 boxes per day)
Study: 790146
Drug: Intensive consolidation
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive consolidation therapy in a protected environment unit with antibiotic prophylaxis
Study: 790146
Drug: Intensive consolidation
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive consolidation therapy in a protected environment unit without antibiotic prophylaxis
Study: 790146
Drug: Early consolidation
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early consolidation therapy
Study: 1581404
Drug: Conventional maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional maintenance therapy
Study: 28323986
Drug: Chronic intranasal
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic intranasal insulin treatment (40 IU, 4 times daily)
Study: 27045264
Drug: Tadalafil 5
Normalized name: tadalafil 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 5 mg once daily (OaD)
Study: 23404788
Drug: Taspoglutide 20
Normalized name: Taspoglutide
DrugBank: Taspoglutide (DB14027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taspoglutide 20 mg (10 mg for first 4 weeks)
Study: 16979854
Drug: Sensory‐motor‐oral stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensory‐motor‐oral stimulation and non‐nutritive sucking
Study: 11699736
Drug: Braun Oral-B
Normalized name: bran Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Braun Oral-B children's power toothbrush (D10)
Study: 8199828
Drug: Intravesical instillations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillations with immuno‐ or chemotherapy
Study: 31387606
Drug: Verubecestat 12
Normalized name: Verubecestat
DrugBank: Verubecestat (DB12285)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verubecestat 12 mg
Study: 31387606
Drug: Verubecestat 40
Normalized name: Verubecestat
DrugBank: Verubecestat (DB12285)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verubecestat 40 mg
Study: 28784336
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oestrogen daily (low-dose group)
Study: 28784336
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg oestrogen daily (high-dose group)
Study: 15140632
Drug: Isradipine (0-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (0-10 mg/70 kg, p.o.)
Study: 15140632
Drug: Dextromethorphan (0-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan (0-60 mg/70 kg, p.o.)
Study: 12658070
Drug: Naloxone (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.15 mg/70 kg, i.m.)
Study: 23860288
Drug: Carbohydrate supplementation
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate supplementation (0.5 g·kg·h)
Study: 20942276
Drug: Deanxit, oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deanxit, oral administration for eight weeks.
Study: 18769066
Drug: ORS +
Normalized name: Orserdu
DrugBank: Elacestrant (DB06374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORS + 25 g PHGG
Study: 18769066
Drug: ORS +
Normalized name: Orserdu
DrugBank: Elacestrant (DB06374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORS + 50 g PHGG
Study: 16948480
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (1.2 g/kg body mass whey protein + 0.3 g/kg body mass sucrose powder, N = 9: 6 female, 3 male)
Study: 14514574
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (2 g/day) for 4 weeks
Study: 1570227
Drug: Controlled-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release morphine 30-mg tablets (MSC) administered orally
Study: 6399444
Drug: Four drugs
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four drugs commonly used for pain relief (specific drugs not mentioned)
Study: 17429632
Drug: Conventional 2-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional 2-hour infusion of l-HOP (oxaliplatin)
Study: 23421309
Drug: Sucrose solution
Normalized name: TootSweet 24% Oral Sucrose Solution
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose solution (control)
Study: 8860096
Drug: Insulin sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin sensitivity index (S(I))
Study: 6376229
Drug: Cimetidine 1
Normalized name: cimetidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1 g, trimipramine 50 mg, prostaglandin E1 analogue 800 or 200 micrograms, low-dose antacid or placebo (antiulcer treatment)
Study: 25060950
Drug: B0.25 group
Approvals — FDA: no, EMA: no, PMDA: no
Description: B0.25 group (3.75mg hyperbaric bupivacaine 2.5mg/ml)
Study: 11369834
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of established severe anaemia in patients with ESRD
Study: 22506497
Drug: Local sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local sequential context provided by preceding facial expressions
Study: 9357378
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal spray (2 sprays per nostril bid)
Study: 8238830
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg.kg‐1 and Alfentanil 50 micrograms.kg‐1
Study: 6354230
Drug: i.v. infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. infusion of insulin, 70 mu. kg‐1h‐1 for the first 60 min and 35 mu. kg‐1h‐1 subsequently
Study: 27239994
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral management (S)
Study: 22661278
Drug: Reduced-intensity modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-intensity modified constraint-induced movement therapy (mCIMT)
Study: 17666600
Drug: IV ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV ferric carboxymaltose (less than or equal to 1,000 mg over 15 minutes, repeated weekly)
Study: 17666600
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous sulfate (FeSO(4) 325 mg orally thrice daily for 6 weeks)
Study: 8814685
Drug: Carboplatin 400
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin 400 mg/m2 as a single agent (CB)
Study: 8814685
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of carboplatin 300 mg/m2, epirubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 (CB‐EC)
Study: 28648477
Drug: Early antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early antibiotic administration (mean TTA 4.35h, 58.5% received first dose within 4h)
Study: 14971863
Drug: Clozapine (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (450 mg/day)
Study: 14971863
Drug: Olanzapine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (50 mg/day)
Study: 9071645
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (hGH) treatment for 2 years
Study: 15121021
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg iv ibandronate injections
Study: 9461704
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy with monitoring of myoglobin concentration, CPK, and CK-MB activity.
Study: 27370230
Drug: Metformin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin with atorvastatin
Study: 23608625
Drug: Biotene OralBalance®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biotene OralBalance® gel
Study: 19931408
Drug: human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: human insulin B‐chain in incomplete Freund's adjuvant (IFA)
Study: 16500657
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Sulphadoxine-pyrimethamine and Artesunate (SP+AS)
Study: 14645311
Drug: Olanzapine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5 to 20 mg/d) with prophylactic benztropine (1 to 4 mg/d)
Study: 14645311
Drug: Haloperidol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (5 to 20 mg/d)
Study: 31109198
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol (CBD) 400 or 800 mg, once daily for 3 consecutive days
Study: 25907999
Drug: 0.0015% Tafluprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0015% Tafluprost ophthalmic solution
Study: 21831448
Drug: Adjunctive creatine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive creatine 4 g daily for 8 weeks
Study: 11262678
Drug: Post administration
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post administration of the VCM1 questionnaire
Study: 9557911
Drug: Esmolol 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 4.0 mg.kg(‐1) IV given 90 secs prior to tracheal intubation
Study: 9557911
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.5 ml. 10kg(‐1) prior to eye bandaging and tracheal extubation
Study: 2758870
Drug: Cefotaxime 1
Normalized name: cefotaxime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime 1 g (i.m.) every 12 h
Study: 7769502
Drug: Quinapril hydrochloride,
Normalized name: Quinapril Hydrochloride, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril hydrochloride, once a day for 8 weeks, with optional titration to a higher dose after 4 weeks based on DBP response.
Study: 581116
Drug: Micronized oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized oestradiol (1, 2 or 4 mg)
Study: 28328303
Drug: 11 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11 sessions of cell phone-delivered smoking cessation treatment
Study: 24852505
Drug: Individualized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized treatment (specific, individualized postural and movement retraining, stretching, and functional weight‐bearing, strengthening exercises)
Study: 15292108
Drug: Oral L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral L-carnitine (2 g/d) + acetyl-L-carnitine (1 g/d)
Study: 15292108
Drug: L-carnitine/acetyl-L-carnitine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine/acetyl-L-carnitine + 1 x 30-mg cinnoxicam suppository every 4 days
Study: 12008655
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody therapy with autologous peripheral blood stem cell transplantation
Study: 25421879
Drug: Nebulized sodium
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized sodium nitrite (AIR001) at a maximum tolerated dose (MTD) of 90 mg administered every 8 hours for 6 days
Study: 25421879
Drug: Nebulized sodium
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized sodium nitrite (AIR001) at higher dosage levels (120 mg and 176 mg)
Study: 25698164
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (CPT) for PTSD
Study: 7980302
Drug: Amniotomy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amniotomy plus oxytocin infusion
Study: 4850376
Drug: oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration of digoxin (0.25 mg)
Study: 4850376
Drug: intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous administration of digoxin (0.25 mg)
Study: 4850376
Drug: urinary excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: urinary excretion of digoxin
Study: 23733488
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg saffron tablets for 7 days
Study: 23733488
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg saffron tablets for 7 days
Study: 24381222
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplement (LNS)
Study: 22873342
Drug: Antiretroviral drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral drugs
Study: 22258269
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplement (LNS) with antiretroviral drugs
Study: 22258269
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplement (LNS) without antiretroviral drugs
Study: 2314405
Drug: Bovine surfactant
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bovine surfactant (20-40 mg/kg in group 1, 40-50 mg/kg in group 2)
Study: 20870753
Drug: Nebulized gentamicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized gentamicin, 80 mg, twice daily for 12 months
Study: 15223674
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (400 mg four times per day)
Study: 9642893
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Treatment (STD)
Study: 7702421
Drug: Captopril treatment
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril treatment
Study: 2071264
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg of garlic powder for four weeks
Study: 6868954
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g of myoinositol daily for 2 months
Study: 21244601
Drug: Concurrent subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent subcutaneous interleukin‐2 (IL‐2), interferon‐α2b (IFN‐α) and granulocyte‐macrophage colony‐stimulating factor (GM‐CSF)
Study: 21275334
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy CD creation intervention
Study: 12538369
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin E emulsion (all‐rac‐alpha‐tocopherol)
Study: 24077370
Drug: Strength training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength training sessions (twice per week) + in-water training
Study: 15738535
Drug: Trastuzumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab plus chemotherapy (paclitaxel followed by fluorouracil, epirubicin, and cyclophosphamide)
Study: 29168107
Drug: Trastuzumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab plus chemotherapy
Study: 28259855
Drug: Restrictive fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive fluid regimen (≤3.0 L in the first 24 hours)
Study: 28259855
Drug: Liberal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal fluid regimen (≥5.4 L in the first 24 hours)
Study: 19226541
Drug: Non-steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drugs (NSAIDs) used for less than the study duration
Study: 15569202
Drug: Alternative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative therapy use
Study: 11022070
Drug: 3 intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 intra-articular injections of 40 mg triamcinolone acetonide
Study: 11022070
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL physiological saline solution (placebo)
Study: 9288302
Drug: Caldwell‐Luc (C‐L)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caldwell‐Luc (C‐L) operations
Study: 8143886
Drug: zolpidem, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: zolpidem, 10 mg for 2 weeks (nights 8-21)
Study: 3046587
Drug: Multiple insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple insulin injections (MI)
Study: 28681550
Drug: AZL-M/CLD 40/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZL-M/CLD 40/12.5 mg/d (initial dose, could be uptitrated to 80/25 mg)
Study: 15502020
Drug: S(+)-ketamine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(+)-ketamine (75 microg/kg bolus followed by continuous infusion of 1.25 microg . kg(‐1) . min(‐1) for 48 h)
Study: 31597485
Drug: Label treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Label treatments (two levels)
Study: 11903525
Drug: Intravenous valproate
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous valproate
Study: 17054858
Drug: Autologous cytokine-induced
Normalized name: cytosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous cytokine-induced killer cell (CIK) fusion (1.1 - 1.5 x 10^10) via peripheral vein or hepatic artery, administered once every 3 - 4 weeks for 4 times, then once every 4 weeks for 4 times
Study: 8839716
Drug: Slow Rotation
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow Rotation (SR) chemotherapy